Tonight's digest has 27 items: six medchem, and seven each in pharmacology, computational and industry. Highlights include a brain-penetrant covalent PIKfyve inhibitor, the first PCNA-directed PET tracer, J&J's Rybrevant approval in head and neck cancer, and CMS's 340B payment cut.
2026-11-06 · ⚗️siRNA (chemically modified oligonucleotides) · Journal of Medicinal Chemistry
- Four pyrrolidine- and aminocyclopentane-based abasic phosphoramidites were made and placed at various siRNA positions.
- Sense-strand placement loosened the duplex and boosted silencing; one aminocyclopentane isomer was most potent, and a seed-region stereoisomer curbed miRNA-like off-targets.
- In mice, the potent variant improved liver knockdown and the seed variant cut off-target transcripts; a 3′-terminal unit added nuclease resistance and served as a conjugation handle.
💡 PointsBased on the abstractDestabilizing the duplex with an abasic unit is a known way to favor guide-strand loading, so the potency gain is expected; the interesting part is that seed off-target behavior flips with stereochemistry. Missing: a head-to-head against GNA or 2′-5′-linked seed modifications, and a test of whether the amino charge, not geometry, drives the effect. Worth trying next: the 3′ amine as a GalNAc attachment point in vivo.
Synthesis of Amino-Functionalized Abasic Monomers as Versatile Building Blocks for siRNA Modification ↗
2026-11-06 · ⚗️PIKfyve lipid kinase; covalent inhibitor (DUN'058) · ACS Chemical Biology
- Covalent hits from live-cell chemoproteomics were optimized for potency, selectivity and brain exposure using mass spectrometry, biochemical and in vivo assays.
- The compound, DUN'058, modifies a cysteine on a flexible loop away from the active site, showing chemoproteomics can reveal unexpected ligandable residues.
- Treatment activates TFEB-linked clearance pathways, and in mice target occupancy in brain persists well after the compound has cleared from circulation.
💡 PointsBased on the abstractA cysteine on a flexible loop away from the ATP site means selectivity likely comes from residue accessibility rather than hinge binding, a different game from reversible chemotypes like apilimod. Needed: a Cys-to-Ser mutant control and proteome-wide engagement at brain-relevant dose, plus resynthesis rate: durable occupancy makes chronic PIKfyve blockade (vacuolation) a real liability to test.
Chemoproteomics Discovery of a Central Nervous System-Penetrant Covalent Inhibitor of PIKfyve ↗
2026-11-06 · ⚗️Polyphosphate kinases PPK1/PPK2 of Pseudomonas aeruginosa; ebselen-based small molecules · Journal of Medicinal Chemistry
- Ebselen-derived compounds were developed to inhibit both PPK1 and PPK2 from Pseudomonas aeruginosa, disrupting the bacterium's polyphosphate balance.
- Lead analogs lowered intracellular polyphosphate and reproduced the ppk-knockout phenotype: weaker biofilms, reduced motility and less pyoverdine and pyocyanin.
- In a Galleria infection model they enhanced meropenem activity, and the representative compounds showed no detectable toxicity to mammalian cells.
💡 PointsBased on the abstractEbselen is a classic promiscuous Se–N electrophile that arylselenylates cysteines, so dual PPK1/PPK2 inhibition likely reflects covalent thiol engagement rather than a tuned binding mode. Still open: thiol-reactivity counter-screens (GSH, unrelated Cys enzymes) and a ppk-null strain showing the phenotype and meropenem synergy are on-target. The obvious follow-up is tuning benzisoselenazolone electrophilicity for selectivity.
Discovery of Ebselen Analogs as Novel Inhibitors of Polyphosphate Metabolism to Attenuate Virulence and Show Combination Benefit with Meropenem in Pseudomonas aeruginosa ↗
2026-11-06 · ⚗️Thrombin; sulfated chimeric peptide anticoagulants (sulfo-XC43-Hiru analogues) · Journal of Medicinal Chemistry
- A rapid, high-throughput workflow was set up to assemble many modified peptide analogues in parallel.
- Variants derive from a chimeric sulfopeptide combining a flea-derived fragment with a leech hirudin segment.
- Non-canonical residues were placed at selected positions to probe non-native structural motifs.
- Each analogue was assessed for thrombin inhibition and resistance to cleavage, linking sequence changes to activity.
💡 PointsBased on the abstractThe sulfotyrosine is the liability to watch: in hirudin-type exosite-I binders the sulfated Tyr boosts affinity, yet sulfate esters are acid-labile and awkward to install in parallel. I'd want a head-to-head against bivalirudin and a plasma stability readout, not just buffer protease assays. Next step: swap in a sulfotyrosine mimetic (sulfonate or difluoromethylene phosphonate) to decouple potency from the labile ester.
Exploring Structure−Activity Relationships by Engineering Modified Thrombin Inhibitors from the Flea Xenopsylla cheopis ↗
2026-11-06 · ⚗️PCNA-targeted 18F PET tracer (small molecule) · Journal of Medicinal Chemistry
- Fluorine-18 tracer [18F]FPON, derived from the clinical PCNA inhibitor AOH1996, enables noninvasive imaging of a target tied to glioma stem cells and therapy resistance.
- It binds PCNA like the parent drug and is made in one radiolabeling step, in modest yield and high purity.
- The tracer enters the brain and stays largely intact; in orthotopic glioma xenografts uptake was specific, blocked by AOH1996, supporting companion-diagnostic use.
💡 PointsBased on the abstractBlocking by AOH1996 shows target-mediated uptake, but PCNA is abundant in every cycling cell, so the decisive number is tumor-to-normal-brain contrast, not absolute uptake. Controls to ask for: an inactive analog as a negative control, logD and P-gp efflux data for the fluorinated analog, and a non-proliferative lesion to test whether the signal tracks proliferation or just disrupted BBB.
Design, Synthesis, and Preclinical Evaluation of [ 18 F]FPON, a First-In-Class PET Tracer Targeting Proliferating Cell Nuclear Antigen for Glioblastoma Imaging ↗
2026-11-06 · ⚗️RNA-targeting small molecule with Fe(II)-coordinating cleavage warhead (r(CUG) repeats, DM1) · bioRxiv
- A small, fully synthetic Fe(II)-binding cleaving group is tested as a substitute for bulky natural-product warheads such as bleomycin.
- Attached to a ligand that recognizes expanded r(CUG) repeats, it degrades the pathogenic RNA while leaving wild-type and short-repeat transcripts largely intact.
- In DM1 patient myoblasts, this lowered nuclear foci, MBNL1 sequestration and splicing defects, with no DNA damage reported.
💡 PointsBased on the abstractSelectivity here comes from the ligand, not the warhead: Fe-based cleavers make diffusible radicals, so any RNA or DNA near the bound molecule is at risk, and a no-DNA-damage claim needs transcriptome-wide data. The key missing control is a non-binding ligand analog carrying the same warhead. A fair comparison would be potency per cell exposure against a RIBOTAC-style recruiter on the same CUG ligand.
A Minimal Synthetic Cleavage Module Enables Selective Degradation of Pathogenic r(CUG) Repeats in Cells ↗
2026-11-04 · 🧬FcRn recycling of multi-format antibodies · bioRxiv
- A panel of rationally designed antibody geometries was tested in orthogonal in vitro assays to see how spatial layout affects FcRn-mediated recycling. Placing Fab domains at the C-terminus (invertbodies) improved recycling, while crowding the N-terminus impaired it.
- Architecture and affinity-enhancing Fc mutations acted independently but cooperatively, pointing to a physiological ceiling on recycling. Non-specific endocytosis was affected only modestly.
- In humanized FcRn mice, architecture produced large differences in clearance that disappeared in FcRn-knockout mice. An invertbody variant of golimumab cleared more slowly without losing potency.
💡 PointsBased on the abstractWould I trust a humanized-FcRn mouse to rank half-lives in people? It's a good mechanism check, and the knockout control is reassuring, but cynomolgus data and target-mediated disposal often reshuffle the order. Also, a rearranged format is a new molecule: immunogenicity, aggregation and manufacturability of C-terminal Fabs need to be shown before the longer half-life counts as a win.
Spatial architecture of complex antibody formats dictates pharmacokinetics via FcRn-recycling ↗
2026-11-04 · 🧬Multikinase inhibitor plus PD-1 antibody plus chemotherapy; CCR8 and TREM2 antibodies · Science Translational Medicine
- A phase 1b/2 trial tested first-line regorafenib, the PD-1 antibody nivolumab and chemotherapy in mismatch repair–proficient advanced gastric cancer; the primary end point was met, with a high objective response rate.
- Single-cell RNA and T cell receptor sequencing of serial biopsies showed more tumor-reactive CD8 T cells and proinflammatory macrophages, and fewer suppressive regulatory T cells, CAFs, pericytes and tip cells.
- At progression, regulatory T cells reexpanded and lipid-associated macrophage subsets emerged. In mouse resistance models, anti-CCR8 or anti-TREM2 antibodies with PD-1 blockade restored antitumor immunity.
💡 PointsBased on the abstractWhich arm is doing the work? Regorafenib's VEGFR and CSF1R inhibition plausibly explains the drop in pericytes, tip cells and suppressive myeloid cells, but a single-arm combination can't separate that from chemo or PD-1 effects. The CCR8 and TREM2 mouse data are hypothesis-grade: syngeneic models rarely recapitulate acquired resistance, and anti-CCR8 depleting Tregs raises tumor-selectivity and on-target safety questions in humans.
Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer ↗
2026-11-04 · 🧬Tau (PET imaging biomarker) · Science Translational Medicine
- Researchers compared tau PET imaging at baseline and over time in amyloid-positive, cognitively impaired people with early-onset or late-onset Alzheimer's disease, drawing on two separate cohort studies.
- After accounting for amyloid burden and clinical stage, early-onset patients had greater tau retention, wider brain involvement and quicker accumulation.
- Tau signal tracked amyloid levels, cognition and daily function more closely in the early-onset group, pointing to tau as a main driver of decline and suggesting treatment targets may differ by age of onset.
💡 PointsBased on the abstractBefore anyone reads this as proof tau is the better target, ask whether PET signal is causal burden or just a tighter readout of disease stage. Cross-sectional correlations can't separate the two. Still, if tau slopes are steeper in early onset, that cohort could power a smaller, faster trial of an anti-tau agent.
Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease ↗
2026-11-04 · 🧬TWEAK–TNFRSF12A signaling · Science Translational Medicine
- Some psoriasis patients treated with biologics against TNF, IL-17 or IL-23 develop eczema-like lesions resembling atopic dermatitis; the molecular drivers were unclear.
- Single-cell and spatial transcriptomic maps of patient skin showed expanded myeloid and T cell populations and keratinocytes shaped by TWEAK acting through its receptor TNFRSF12A.
- In cultured keratinocytes, TWEAK combined with IL-13 induced a type 2 and interferon-skewed epithelial program that partly reproduced the lesional signature.
💡 PointsBased on the abstractCultured keratinocytes plus recombinant cytokines show sufficiency at best, so I'd ask first whether TWEAK-high, TNFRSF12A-high skin predicts who flips to eczema before treatment. Then check drug exposure in skin, and whether blockade quiets the lesion without unmasking psoriasis again.
TWEAK signaling drives the transition from psoriasis to atopic dermatitis–like inflammation in paradoxical eczema ↗
2026-11-03 · 🧬SGLT2 inhibitor (empagliflozin); integrin signalling · British Journal of Pharmacology
- Empagliflozin was tested for a direct anti-hypertrophic action independent of glucose control, using angiotensin II-stimulated human and rat cardiomyocyte lines and a mouse pressure-overload model.
- It reduced hypertrophy, dysfunction and fibrosis; transcriptomics pointed to extracellular matrix-receptor and focal adhesion pathways, and elevated integrin subunits in diseased hearts were brought back toward normal.
- The integrin blocker ATN-161 abolished the benefit and the FAK/Src/Akt response, indicating integrin dependence, while docking and SP1 knockdown suggested SP1 as a possible link to integrin expression.
💡 PointsBased on the abstractWhat does the ATN-161 rescue really prove? It's a peptide that hits more than one integrin, so losing the benefit shows integrin involvement, not that empagliflozin acts on integrins directly. Before calling this SGLT2-independent, I'd want in vitro concentrations matched to free clinical exposure and an SGLT2-null or genetic control.
Empagliflozin inhibits cardiac hypertrophy via a mechanism involving integrin signalling ↗
2026-11-03 · 🧬RyR2 inhibitor (macrocyclic depsipeptide) · bioRxiv
- ent-Verticilide, a synthetic macrocyclic depsipeptide that inhibits ryanodine receptor 2 and is being explored for cardiac arrhythmias, was profiled for metabolism and pharmacokinetics.
- In liver S9 fractions from mouse, rat, dog and human, the compound was depleted quickly in an NADPH-dependent manner; CYP3A was the main contributing enzyme subfamily, and eight putative metabolites formed mainly by hydroxylation, oxidation and desaturation, similar across human and rat.
- In rats, clearance was high, distribution was extensive and oral bioavailability was low, supporting extensive hepatic oxidative metabolism and giving a first DMPK framework for preclinical work.
💡 PointsBased on the abstractHigh clearance plus low oral exposure is a tough profile for a chronic antiarrhythmic, and S9 depletion alone won't tell you how much is first-pass versus other routes. I'd want unbound plasma and cardiac tissue levels set against RyR2 inhibition potency before blaming metabolism. If CYP3A soft spots are confirmed, blocking them is the obvious step, but the CYP3A drug-interaction burden then needs watching.
Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide ↗
2026-11-03 · 🧬Voltage-gated sodium channels (venom peptide gating modulator) · British Journal of Pharmacology
- Neuronal hyperexcitability driven by voltage-gated sodium channels is proposed as a contributor to spinal muscular atrophy, which could be targeted alongside SMN-restoring therapies.
- In a zebrafish smn1 knockout model, the venom peptide ProTx-III, the approved drug riluzole and the N-type calcium channel blocker ziconotide were compared for effects on movement and lifespan.
- Sodium channel modulation improved locomotion and survival, with ProTx-III outperforming riluzole, while ziconotide gave limited benefit. Electrophysiology showed ProTx-III shifted gating broadly, whereas riluzole mainly stabilised the inactivated state.
💡 PointsBased on the abstractZebrafish larvae can't tell you whether this works in SMA patients, and a venom peptide that hits NaV subtypes broadly is a tool, not a drug. Ask which subtype drives the motor neuron hyperexcitability, and whether human SMA neurons show it too. Without that, riluzole-class stabilisers, with real clinical exposure data, remain the pragmatic comparator.
Selective modulation of NaV channel gating counteracts aberrant hyperexcitability and rescues motor function and survival in a model of spinal muscular atrophy ↗
2026-11-07 · 💻Docking pose-ensemble MLP compound prioritization (LRH-1, NR5A2) · Journal of Chemical Information and Modeling
- Poses from physics-based targeted docking and generative blind docking, across several receptor conformations, train two MLPs that predict binders or activators at the LRH-1 orthosteric pocket, avoiding dependence on one pose or one score.
- On a chemically distinct out-of-distribution set, the models found dissimilar compounds and responded to single-scaffold edits, suggesting use in lead optimization.
- A small prospective campaign produced four putative binders, and combining docking scores with MLP predictions improved hit enrichment across library sizes.
💡 PointsBased on the abstractFour putative binders is a docking-plus-ML result, not a validated one, so I'd want biophysical confirmation (DSF, SPR, or a cocrystal) before calling them hits. LRH-1 pockets are lipophilic and promiscuous, so I'd also check the MLPs against a property-matched decoy set, since pose-derived features can mostly encode lipophilicity and size. The consensus gain over docking alone is the useful, transferable bit.
Computational Compound Prioritization Strategy Incorporating Docking Variability and Interaction Energies Identifies Putative LRH-1 Binders ↗
2026-11-07 · 💻Membrane-binding free energy calculation (PMF, metadynamics, eABF) · Journal of Chemical Theory and Computation
- The authors describe a statistical-mechanical, potential-of-mean-force-based route for quantifying how dilute peripheral membrane proteins bind homogeneous lipid membranes.
- Well-tempered metadynamics and extended adaptive biasing force were used to sample the many noncovalent contacts involved, including cation–π and hydrophobic interactions.
- Applied to a bacterial phosphatidylinositol-specific phospholipase C on phosphatidylcholine membranes, the computed standard binding free energy agreed closely with experimental estimates.
💡 PointsBased on the abstractOne protein on one homogeneous PC bilayer is a friendly test case. Real membranes are anionic, mixed and curved, and metadynamics/ABF convergence there gets much harder. If I wanted this for a peripheral target, I'd first check that the standard-state correction and the orientation/collective-variable choice hold up, and that the result isn't sensitive to the force field's cation-pi and lipid parameters. Agreement to experiment on a single system could still be partly fortuitous.
A Computational Framework for the Determination of the Binding Affinity of Peripheral Proteins to Homogeneous Membranes ↗
2026-11-06 · 💻Active learning with docking for kinase fragment recombination (PKA case study) · chemRxiv
- Framework combines subpocket-aware fragment recombination from KinFragLib, docking, ML surrogate models, and genetic-algorithm-style fragment additions, deletions and substitutions around already-scored ligands.
- Tested retrospectively on protein kinase A in a very large recombination space; only a tiny fraction of ligands needed expensive docking, yet many top-scoring ones were found.
- A greedy acquisition strategy recovered a large share of the best ligands, clearly beating random sampling; a diversity-aware variant broadened fragment and hinge-binder coverage while staying competitive.
💡 PointsBased on the abstractPKA is about the friendliest kinase for this: a rigid, well-studied pocket where docking scores correlate decently with enrichment. Retrospective recovery of docking top-hits only shows the surrogate learns the docking function, not affinity. Before porting this to my target I'd want an orthogonal check, such as FEP or experimental data on a handful of picks, plus synthesizability of the recombined molecules.
Active Learning for Fragment-Based Kinase Inhibitor Discovery using Docking ↗
2026-11-06 · 💻Assay-aware ML evaluation and ranking models for bioactivity prediction · Digital Discovery
- Public bioactivity data clusters by assay origin, so simply guessing a training assay's average activity already performs surprisingly well for compounds from that same assay.
- The authors argue models should prioritize ranking compounds within an assay rather than predicting absolute values on aggregated data.
- On three ChEMBL-derived datasets, rankers trained on same-assay sets outperformed IC50 regression and rankers trained on arbitrary compound sets.
💡 PointsBased on the abstractIf same-assay mean is a strong baseline, then random-split benchmarks on pooled ChEMBL mostly reward assay-identity leakage, so I'd distrust any reported R² there. Before adopting this, check how it holds on a new assay or a new series, where no same-assay anchor exists. In practice it fits lead optimization: a few measured compounds per assay, then rank the rest.
Assay-Based Machine Learning: Rethinking Evaluation in Drug Discovery ↗
2026-11-06 · 💻Target prediction / polypharmacology (deep neural network on ChEMBL35) · chemRxiv
- PPB4 is a deep neural network trained on ChEMBL35 that infers likely targets of a query molecule from its similarity to target-annotated compounds.
- Unlike the earlier PPB3 and comparable tools that report only probable actives, it also flags likely inactive targets, and targets where the query resembles both active and inactive compounds.
- Each predicted target comes with its nearest active neighbors from the training data. Validation is shown through two prospective case studies; no comparative benchmark is described. Free web server.
💡 PointsBased on the abstractFlagging likely inactives is the useful bit: ChEMBL inactives are sparse and assay-dependent, so I'd want to know what threshold defines 'inactive' and how calibrated those calls are. With no head-to-head against PPB3, SEA or similar, and only two case studies, I can't tell if it's better. I'd run it on a few of our compounds with known off-targets before trusting it.
Predicting Active and Inactive Targets of Small Molecules from ChEMBL Data Using the Polypharmacology Browser PPB4 ↗
2026-11-06 · 💻LLM-based de novo molecular generation (quantization benchmark) · chemRxiv
- Four open-source LLMs were run locally at original precision and three weight-quantization levels, testing unconstrained small-molecule generation and generation conditioned on in-context reference kinase inhibitors.
- Quantization raised inference speed, most for two of the models, while unconstrained output quality (validity, uniqueness, drug-likeness, diversity, synthesizability) was unaffected.
- In reference-guided generation, only one model stayed close to the reference chemical space at every precision; two largely ignored it, and another lost adherence at the most aggressive quantization.
💡 PointsBased on the abstractUnconstrained metrics like validity and QED are nearly saturated for any decent LLM, so "quantization doesn't hurt" there is a weak test. The informative result is adherence, and it needs a real control: compare against a trivial baseline (random draws from the reference set, or a plain scaffold-decoration script) using Tanimoto/scaffold overlap and novelty. Before swapping a quantized model into a kinase design loop, I'd rerun this on our own series at our target precision.
Lost in Chemical Space: Local Open-Source Large Language Models Display Model-Dependent Adherence to Reference Data in Molecular Generation ↗
2026-11-05 · 💻Descriptor-based QSPR for cyclodextrin host-guest binding; data noise bound · Journal of Chemical Information and Modeling
- Reproducibility of compiled cyclodextrin inclusion constants was assessed at three levels: within a single calorimetric study, across laboratories and methods, and among replicated host–guest pairs in a standard compilation, which showed a heavy tail of large outliers.
- Propagating this noise through a small modeling set implies an out-of-sample R2 ceiling well below published values; response noise explains most of the leave-one-out error.
- A size descriptor from measured diffusion coefficients was statistically indistinguishable from McGowan volume (each with log P), and both degraded when whole chemical families were held out.
💡 PointsBased on the abstractBefore we trust any R2 from a literature-derived affinity set, I'd want the replicate-based ceiling computed for it. Do it on your own assay-derived data: take the duplicate measurements, estimate the noise variance, and report the achievable R2 next to every model. Also, a 'new' descriptor that ties McGowan volume tells you to stop, not tune. Only family-held-out splits are honest.
A Three-Level Noise Floor for Cyclodextrin Binding Constants and What It Permits for Descriptor-Based Prediction ↗
2026-11-06 · 🏢restructuring · BioSpace · Agios Pharmaceuticals
- Agios is cutting more than 100 R&D roles, over a third of that team, to focus on the mitapivat franchise, with about $11 million of charges this year and savings from 2027.
- The FDA moved the sickle cell disease decision date from November 1 to February 1, 2027 after asking about a safety protocol and whether a REMS is needed. Cash stood at $907 million at quarter end.
💡 PointsBased on public reportsCutting research while the lead indication's review is extended is a bet that mitapivat alone carries the company; profitability is guided only for 2028. A possible REMS would matter commercially more than the delay itself, since sickle cell uptake depends on easy prescribing, and the next question is what pipeline survives the cut.
Agios axes 100-plus R&D roles while awaiting FDA decision ↗
2026-11-06 · 🏢M&A · BioPharma Dive · ANI Pharmaceuticals / Egetis Therapeutics
- ANI Pharmaceuticals offered to buy Egetis Therapeutics for $560 million, at 11.25 Swedish krona a share, a 27% premium to the two-month average price.
- Egetis sells Emcitate, the only treatment approved in the US and Europe for peripheral thyrotoxicosis in Allan-Herndon-Dudley syndrome; ANI expects peak annual sales of up to $300 million.
💡 PointsBased on public reportsANI is moving from generics toward branded rare disease, buying an approved product rather than a pipeline. The $300 million peak figure is ANI's own and rests on a very small patient pool, so the price implies near-full penetration; the 27% premium is thin for a Swedish-listed target, leaving room for a competing bid or holdouts.
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down ↗
2026-11-06 · 🏢regulatory preview · BioSpace · Summit Therapeutics / Capricor / Vertex Pharmaceuticals
- Summit's ivonescimab for EGFR-mutated lung cancer after TKI therapy is due by November 14; it would be the first PD-1xVEGF bispecific cleared in the US. Capricor's DMD cell therapy deramiocel is due November 22 after a 9-3 negative advisory vote.
- Vertex's povetacicept in IgA nephropathy is due by November 30; rivals from Novartis and Vera are already approved. At least 11 action dates fall this month.
💡 PointsBased on public reportsIvonescimab is the cleanest read-through: a progression-free-survival win without a significant overall-survival result at filing, so approval would show how much the FDA discounts a later nominal survival signal. Capricor is the opposite, a negative panel and a prior rejection. Povetacicept is a late entrant, so label and pricing decide how fast it takes share.
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November ↗
2026-11-06 · 🏢partnership · BioPharma Dive · Eli Lilly / Hims & Hers
- Lilly will offer Zepbound and its oral Foundayo through the Hims & Hers telehealth platform at the same self-pay prices available elsewhere, starting at $299 and $149 a month respectively.
- Hims previously sold cheaper compounded GLP-1s and changed course in March after a legal challenge from Novo, which struck a similar deal with it.
💡 PointsBased on public reportsBoth big GLP-1 makers now use Hims as a cash-pay channel, which turns a former adversary into distribution and removes the compounded-versus-branded argument from the telehealth funnel. For Lilly the signal is price discipline: self-pay tiers are set low enough that volume, not margin per script, is the bet. Watch whether Hims keeps compounded options for 'clinical necessity'.
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down ↗
2026-11-06 · 🏢pipeline change · BioSpace · Sarepta Therapeutics
- Sarepta will not restart enrollment in ENVISION, the confirmatory study of Elevidys in non-ambulatory and older patients, which was paused last summer with about half of its target enrolled.
- It plans to give the FDA 12-week safety data from a sirolimus cohort of ENDEAVOR in Q1 2027 and is working to restore the non-ambulatory label. Q3 Elevidys sales fell year on year but beat one analyst's estimate.
💡 PointsBased on public reportsStopping a half-enrolled confirmatory trial leaves the older-patient story resting on a label-restoration negotiation rather than randomized evidence. Dyne's exon-51 decision in January and REGENXBIO's planned 2027 filing mean Sarepta's window to stabilize sales before share erosion is roughly a year; the sirolimus safety data is the near-term catalyst to watch.
Sarepta’s new CEO confident in clinical execution as DMD competitors close in ↗
2026-11-05 · 🏢regulatory action · BioPharma Dive · CMS / 340B hospitals
- CMS finalized its 2027 outpatient rule: Medicare will pay 340B participants the average sales price minus 28%, a smaller cut than proposed, which the agency estimates lowers drug spending by about $5.5 billion in 2027.
- The cut is budget neutral, so payments for non-drug services rise by the same amount; imaging without contrast moves to site-neutral rates. The American Hospital Association called it an assault on 340B.
💡 PointsBased on public reportsThe money moves from 340B hospitals to non-participating ones, not out of the system, so the effect on drugmakers is indirect: less hospital margin may push 340B systems to fight rebate-model changes harder. Manufacturers get no price relief here, but the rule gives them a data point that CMS will cut 340B reimbursement administratively, without Congress.
Medicare will cut billions from 340B, expand site-neutral payments in 2027 ↗
2026-11-05 · 🏢regulatory approval · Endpoints News · Johnson & Johnson
- The FDA granted accelerated approval to subcutaneous amivantamab (Rybrevant Faspro) for recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and a PD-(L)1 antibody; HPV-associated oropharyngeal disease is excluded.
- It rests on a single-arm cohort of the Phase 1b/2 OrigAMI-4 study, with confirmatory trials required; the FDA called it the first new drug for this setting in a decade.
💡 PointsBased on public reportsThis is the first indication outside lung cancer for the EGFR/MET bispecific, and a single-arm response-rate approval means the Phase 3 OrigAMI-5 first-line study now carries the franchise's credibility. Cetuximab remains the comparator everyone will cite; with no randomized data, the open question is how much of the response translates into survival.
J&J’s Rybrevant nets FDA approval in head and neck cancer ↗
